№ lp_1_2_06562
File format: docx
Character count: 11952
File size: 134 KB
Note:
Year
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Contextual Description:
A fact sheet referencing various studies and research articles on Glioblastoma Multiforme, including treatment options and clinical trials.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Organization:
American Physical Therapy Association (APTA) – Neurology Section
Document Type:
Fact Sheet
Medical Condition:
Glioblastoma Multiforme (GBM)
Target Audience:
Healthcare professionals, patients, caregivers
Diagnostic Methods:
MRI, biopsy
Treatment Methods:
Surgery, radiation therapy, chemotherapy (Temozolomide), tumor-treating fields (TTFields)
Epidemiology:
Incidence 2–3 per 100,000 adults per year, median age 64, higher prevalence in men and Caucasians
Survival Rates:
26–33% at 2 years, 4–5% at 5 years
Risk Factors:
Ionizing radiation, certain chemical exposures, genetic syndromes (neurofibromatosis, tuberous sclerosis, Li-Fraumeni, retinoblastoma, Turcot syndrome)
Contact:
ANPT, Phone 952.646.2038, [email protected]
Note:
, www.neuropt.org
Year:
2023
Region / City:
United States
Topic:
Glioblastoma Multiforme, Physical Therapy, Research Updates
Document Type:
Fact Sheet
Organization:
ANPT
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Target Audience:
Healthcare professionals, patients with GBM, caregivers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Document Type:
Supplementary research methods
Research Field:
Tumor immunology
Disease Focus:
Glioblastoma multiforme
Molecular Focus:
ICOSLG-mediated signaling and IL-10–producing regulatory T cells
Experimental Models:
Human glioma stem cells, murine RasR2 glioma-initiating cells, CD4+ naïve T cells
Biological Materials:
Patient-derived neurospheres, peripheral blood mononuclear cells
Techniques:
Flow cytometry, immunofluorescence staining, luciferase reporter assay, siRNA transfection, hypoxia induction, cytometry by time-of-flight (CyTOF)
Cell Culture Conditions:
Defined DMEM/F12 medium with B27, heparin, EGF, and bFGF
Key Molecular Targets:
ICOSLG, NF-κB, Foxp3, STAT5, PD-L1, HLA molecules
Reagents and Antibodies:
Commercial reagents and antibodies from multiple biotechnology suppliers
Associated Experiments:
Analysis of ICOSLG expression, NF-κB promoter activity, tumor-conditioned medium effects on T cells
Source Material:
Surgical glioma specimens and established experimental cell lines
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Organization:
American Physical Therapy Association (APTA) – Neurology Section
Document Type:
Fact Sheet
Medical Condition:
Glioblastoma Multiforme (GBM)
Target Audience:
Healthcare professionals, patients, caregivers
Diagnostic Methods:
MRI, biopsy
Treatment Methods:
Surgery, radiation therapy, chemotherapy (Temozolomide), tumor-treating fields (TTFields)
Epidemiology:
Incidence 2–3 per 100,000 adults per year, median age 64, higher prevalence in men and Caucasians
Survival Rates:
26–33% at 2 years, 4–5% at 5 years
Risk Factors:
Ionizing radiation, certain chemical exposures, genetic syndromes (neurofibromatosis, tuberous sclerosis, Li-Fraumeni, retinoblastoma, Turcot syndrome)
Contact:
ANPT, Phone 952.646.2038, [email protected]
Note:
, www.neuropt.org
Year:
2023
Region / City:
United States
Topic:
Glioblastoma Multiforme, Physical Therapy, Research Updates
Document Type:
Fact Sheet
Organization:
ANPT
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Target Audience:
Healthcare professionals, patients with GBM, caregivers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
Rome, Italy
Field:
Cancer Research
Document Type:
Article
Organization / Institution:
Sapienza University of Rome, University of Milan, Consiglio Nazionale delle Ricerche (CNR), University of Trento, University of Ferrara
Authors:
Guerriero, Claudia; Manfredelli, Marianna; Matera, Carlo; Iuzzolino, Angela; Conti, Luciano; Dallanoce, Clelia; De Amici, Marco; Trisciuoglio, Daniela; Tata, Ada Maria
Target Audience:
Researchers in Cancer Biology
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Keywords:
glioblastoma; cancer stem cells; M2 muscarinic receptor; orthosteric and dualsteric muscarinic agonism; autophagy; apoptosis; mTORC1
Funding:
Ateneo Sapienza Funds
References:
Aoki H, 2008, Autophagy, V4, P467, DOI 10.4161/auto.5668
Context:
Scientific article exploring the role of M2 muscarinic receptor stimulation in inducing autophagy and apoptosis in glioblastoma cancer stem cells, and the differential effects of orthosteric and dualsteric agonists.
Document Type:
Supplementary research methods
Research Field:
Tumor immunology
Disease Focus:
Glioblastoma multiforme
Molecular Focus:
ICOSLG-mediated signaling and IL-10–producing regulatory T cells
Experimental Models:
Human glioma stem cells, murine RasR2 glioma-initiating cells, CD4+ naïve T cells
Biological Materials:
Patient-derived neurospheres, peripheral blood mononuclear cells
Techniques:
Flow cytometry, immunofluorescence staining, luciferase reporter assay, siRNA transfection, hypoxia induction, cytometry by time-of-flight (CyTOF)
Cell Culture Conditions:
Defined DMEM/F12 medium with B27, heparin, EGF, and bFGF
Key Molecular Targets:
ICOSLG, NF-κB, Foxp3, STAT5, PD-L1, HLA molecules
Reagents and Antibodies:
Commercial reagents and antibodies from multiple biotechnology suppliers
Associated Experiments:
Analysis of ICOSLG expression, NF-κB promoter activity, tumor-conditioned medium effects on T cells
Source Material:
Surgical glioma specimens and established experimental cell lines
Document Type:
Supplementary Methods
Scientific Field:
Molecular Biology; Cancer Biology; Nanomedicine
Research Focus:
Exosome-mediated delivery of metformin and siRNA in glioblastoma cells
Biological Materials:
Primary GBM cells (N9, TBD0220); murine brain endothelial cells (bEnd.3); GBM cell lines (GL261, CT2A); neuronal cells (HT22); astrocyte cells (C8-DIA)
Key Molecules:
PTRF protein; cPLA2; metformin; siRNA (siPTRF, chol-sicPLA2)
Experimental Techniques:
Cell culture; lentiviral transfection; siRNA transfection; ultracentrifugation; western blot analysis; confocal laser scanning microscopy; flow cytometry; FRAP membrane fluidity assay; electroporation; nanoparticle tracking analysis; transmission electron microscopy; dynamic light scattering; high-performance liquid chromatography; Seahorse extracellular flux analysis
Biological Structures Studied:
Blood-derived exosomes
Analytical Software:
ImageJ
Laboratory Equipment:
CLSM (FV1200 Olympus); NanoSight NS300; JEM-2100F TEM; Bio-Rad Gene Pulser Xcell Electroporation System; Seahorse XF24 Analyzer
Chemical Reagents:
fetal bovine serum; metformin; DiI dye; Cy5 dye; oligomycin; FCCP; rotenone; antimycin A
Purpose of Experiments:
Investigation of cellular uptake, membrane fluidity, mitochondrial function, and delivery efficiency of engineered exosomes in GBM cells
Geographical Reference of Reagents:
Shanghai, China; Suzhou, China; Beijing, China; USA
Year:
2017
Institution:
The University of Texas MD Anderson Cancer Center
Region / City:
Houston, TX, USA
Document type:
Supplementary materials
Subject:
Glioblastoma stem cells, REST and DRD2 pathways
Methods:
Cell culture, immunofluorescence, RNA preparation, qRT-PCR, chromatin immunoprecipitation, genome-wide expression analysis, Western blot, ChIP-Seq
Target audience:
Researchers in molecular biology and oncology
Approval:
Institutional review board approved
Experimental models:
HR-GSC1, HR-GSC2, LR-GSC cell lines
Key reagents:
Lentiviral vectors, antibodies, Trizol, microarrays
Analysis software:
Agilent GeneSpring GX, Ingenuity Pathway Analysis
Supplementary content:
Materials and methods, figure legends
Year:
2025
Region / City:
New York, USA
Subject:
Immigration, Habeas Corpus
Document Type:
Legal Memorandum
Organization / Institution:
United States District Court for the Southern District of New York
Author:
[Client Name]
Target Audience:
Legal professionals, Court
Period of Validity:
Ongoing
Approval Date:
[Date]
Date of Changes:
[Date]
Year:
2024
Region / City:
Northwest Florida
Subject:
Environmental Resource Permitting, Stormwater Management
Document Type:
Handbook
Agency / Institution:
Florida Department of Environmental Protection, Northwest Florida Water Management District
Author:
Florida Department of Environmental Protection, Northwest Florida Water Management District
Target Audience:
Permit applicants, engineers, environmental consultants
Period of Validity:
N/A
Approval Date:
June 28, 2024
Date of Changes:
N/A
Note:
Year
Subject:
Early Intervention
Document Type:
Guidelines
Organization / Institution:
NYS Department of Health
Target Audience:
Early Intervention Service Providers
Language:
English
Document type:
Manuscript template
Intended use:
Scholarly article preparation
Structure elements:
Abstract, sections, subsections, figures, tables, references
Affiliation format:
Department, Institution, City, Country
Author information:
Author names and e-mail placeholder
Citation style:
Numbered references
Figure and table captions:
Included as placeholders
Content status:
Placeholder and sample text
Year:
2024
Date:
23 October 2024
Organization:
International Telecommunication Union Radiocommunication Sector
Study Group:
Radiocommunication Study Groups
Working Party:
Working Party 4B
Document identifiers:
Document 4B/TEMP/17; Document IMT-2020-SAT/5-E
Language:
English
Subject:
IMT-2020 satellite radio interface specifications
Related Recommendation:
ITU-R M.[IMT-2020-SAT.SPECS]
Scope:
Global Core Specification, references, notifications and certifications for IMT-2020 satellite component
Administrative status:
Working document
Version:
July 2024
Reference Style:
CSE 9th Citation–sequence
In-text Citations:
Superscript numbers
Quotations:
American or British style
Abbreviations:
Defined at first mention
Spelling:
American or British style
Punctuation:
Oxford comma
Numbers and Dates:
Numerals, date format Year month day
Year:
2015
Region / City:
Uzbekistan
Topic:
Maternal and Child Health Services
Document Type:
Report
Organization / Institution:
UNICEF
Author:
UNICEF Uzbekistan
Target Audience:
Policymakers, health professionals, international development organizations
Period of Validity:
2012-2015
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Region / city:
Oxford
Subject:
Referencing, Academic Writing
Document Type:
Research Guide
Organization:
Oxford Brookes University
Author:
Pears, R., Shields, G.J.
Target Audience:
Students, Researchers
Period of Use:
Ongoing
Approval Date:
2025
Amendment Date:
N/A
Year:
2023
Region / city:
Global
Subject:
Telecommunications, 5G System, Protocols, Standards
Document type:
Technical Specification
Author:
3rd Generation Partnership Project (3GPP)
Target audience:
Engineers, Technical Experts, Telecommunications Specialists
Period of validity:
Ongoing
Approval date:
Not specified
Date of amendments:
Not specified
Year:
2026
Region / City:
Not specified
Topic:
Citations and references management
Document Type:
Instructional guide
Institution:
Great Ormond Street Institute of Child Health Library
Audience:
Users of EndNote with Word (Mac)
Effective Date:
Not specified
Date of Last Update:
Not specified
Year:
1997
Region / City:
USA
Topic:
Animal Welfare, IACUC Regulations
Document Type:
Guidance, Regulations
Agency / Institution:
OLAW, USDA
Author:
Not specified
Target Audience:
Institutional Animal Care and Use Committees (IACUC), Research Institutions
Period of Validity:
Ongoing
Approval Date:
June 2, 1997
Date of Changes:
March 18, 2011